ArticleInternational journal of breast cancer2024

Subcutaneous Trastuzumab: An Observational Study of Safety and Tolerability in Patients With Early HER2-Positive Breast Cancer.

Iris Otoya et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.